プロテオミクス - 世界市場の考察、競合情勢、市場予測（2030年）

世界のプロテオミクスの市場規模は、2024年～2030年の予測期間にCAGRで13.54%の成長が見込まれます。市場は主に、さまざまな慢性疾患や標的疾患を治療するための個別化医療に対する需要の高まりにより、大きな市場成長を示しています。さらに、標的疾患の治療における先進診断へのニーズの高まり、がん、心血管疾患（CVD）、呼吸器疾患、慢性腎臓病（CKD）などのさまざまな標的疾患の世界中での高い有病率、疾患の診断と治療に向けた医薬品設計、バイオマーカー発見、臨床診断における製品使用への注目の高まりが、市場におけるプロテオミクスのニーズを生み出します。さらに、製品およびサービスの発売と承認の増加、市場における主要企業のプレゼンスなどの要因は、市場におけるプロテオミクスの要件を生み出します。最後に、医療部門全体の拡大や、創薬、医療産業の主要企業による投資の急増は、研究開発活動を増加させ、需要に確実に影響を与えます。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

プロテオミクスの市場力学

プロテオミクス市場の重要な促進要因の1つは、がん、心血管疾患などのさまざまな慢性疾患の有病率の上昇です。

例えば、世界保健機関（WHO）（2022）によると、がんは世界の主要死因であり、2020年に約1,000万人が死亡しています。2020年の乳がんの新規症例は、全世界で226万例でした。同じ資料によると、2020年の全世界での新規症例数は、肺がんが221万人、大腸がんが193万人、前立腺がんが141万人、皮膚がんが120万人、胃がんが109万人でした。さらに、WHO（2022）によると、心血管疾患（CVD）は世界の主要死因であり、毎年推定1,790万人の命を奪っています。

プロテオミクスは、バイオマーカーや治療標的を発見するためのユニークなツールを提供することから、がんの予防と治療に寄与することが期待されています。したがって、慢性疾患の有病率の増加は、個別化医療への需要を高め、市場におけるプロテオミクス需要の増加につながります。

プロテオミクス研究開発への投資の増加は、プロテオミクス市場の大きな成長要因の1つです。2022年、National Institutes of Health（NIH）は医学研究に450億米ドルを提供しました。この資金は、疾病の存在を示すバイオマーカーの同定や、疾病の原因となる遺伝子とタンパク質の同定など、疾病が発症する基本的なプロセスを理解しようとする生命科学研究を支援することを目的としていました。また、2020年、Novo Nordisk Foundationがコペンハーゲン大学から質数量分析施設の設立に向け最大150万米ドルの助成金を授与され、タンパク質研究が大きく前進しました。このように、世界中の政府や主要企業によるこのような投資や資金提供は、研究開発活動を活発化させ、ひいてはプロテオミクス市場に影響を与えます。

さらに、医療コストの上昇や、オーダーメイドの薬に対する需要の高まり、遺伝性疾患の割合の増加が、予測期間にプロテオミクスの需要を増加させます。

したがって、上記の要因が総合的に、2024年～2030年の予測期間にプロテオミクス市場全体を牽引します。

しかし、器具の高いコストや、あいまいな規制枠組みの存在などが、プロテオミクス市場の成長にとっての課題となる可能性があります。

プロテオミクス市場は、COVID-19パンデミックの期間にプラスの影響を受けました。パンデミックの初期段階では、プロテオミクスの器具とサービスの需要は、厳格なロックダウン規則が課され、製造と供給が中断されたために落ち込みを見せました。しかし、プロテオミクスの手法と器具は、ワクチン開発に向けてバイオマーカーを調査するために、COVID-19ワクチンの開発に使用されました。さらに、プロテオミクスのアプローチは、タンパク質とその翻訳後修飾の定量と差次的発現を提供できるため、COVID-19の研究に適していました。このように、COVID-19ワクチンの調査が増えるにつれて、プロテオミクスの器具とサービスに対する需要は大きく高まります。同様に、ロックダウン規制の緩和、リソースとサプライチェーンの好転、大衆へのワクチン投与、研究開発活動におけるプロテオミクス需要の増加により、プロテオミクスの需要は増加し、2022年～2028年の予測期間も同様に増加すると見込まれます。

当レポートでは、世界のプロテオミクス市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 プロテオミクス市場レポートのイントロダクション

第2章 プロテオミクス市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

第4章 プロテオミクス市場の主な要因の分析

• プロテオミクス市場の促進要因
• プロテオミクス市場の抑制要因と課題
• プロテオミクス市場の機会

第5章 プロテオミクス市場のポーターのファイブフォース分析

第6章 プロテオミクス市場に対するCOVID-19の影響分析

第7章 プロテオミクス市場のレイアウト

• 製品・サービス別
  • 計装技術
  • 試薬・消耗品
  • ソフトウェア、サービス
• 用途別
  • 臨床診断
  • 創薬
  • その他
• エンドユーザー別
  • 病院
  • 臨床検査室
  • 製薬企業
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 プロテオミクス市場の企業と製品のプロファイル

• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher.
• General Electric Company
• Bruker
• Merck KGaA
• Promega Corporation.
• Waters Corporation.
• Illumina, Inc.
• Creative Proteomics.
• VProteomics
• HORIBA, Ltd.
• Applied Biomics.
• Fios Genomics.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Proteomics Market
• Table 3: Proteomics Market Analysis in Global (2021-2030)
• Table 4: Proteomics Market Analysis in Global by Product Type (2021-2030)
• Table 5: Proteomics Market Analysis in Global by Application (2021-2030)
• Table 6: Proteomics Market Analysis in Global by End-User (2021-2030)
• Table 7: Proteomics Market Analysis in Global by Geography (2021-2030)
• Table 8: Proteomics Market Analysis in North America (2021-2030)
• Table 9: Proteomics Market Analysis in North America by Country (2021-2030)
• Table 10: Proteomics Market Analysis in the US (2021-2030)
• Table 11: Proteomics Market Analysis in Canada (2021-2030)
• Table 12: Proteomics Market Analysis in Mexico (2021-2030)
• Table 13: Proteomics Market Analysis in Europe (2021-2030)
• Table 14: Proteomics Market Analysis in Europe by Country (2021-2030)
• Table 15: Proteomics Market Analysis in France (2021-2030)
• Table 16: Proteomics Market Analysis in Germany (2021-2030)
• Table 17: Proteomics Market Analysis in the UK (2021-2030)
• Table 18: Proteomics Market Analysis in Italy (2021-2030)
• Table 19: Proteomics Market Analysis in Spain (2021-2030)
• Table 20: Proteomics Market Analysis in the Rest of Europe (2021-2030)
• Table 21: Proteomics Market Analysis in Asia-Pacific (2021-2030)
• Table 22: Proteomics Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 23: Proteomics Market Analysis in China (2021-2030)
• Table 24: Proteomics Market Analysis in Japan (2021-2030)
• Table 25: Proteomics Market Analysis in India (2021-2030)
• Table 26: Proteomics Market Analysis in Australia (2021-2030)
• Table 27: Proteomics Market Analysis in South Korea (2021-2030)
• Table 28: Proteomics Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 29: Proteomics Market Analysis in the Rest of the World (2021-2030)
• Table 30: Proteomics Market Analysis in the Rest of the World by Region (2021-2030)
• Table 31: Proteomics Market Analysis in the Middle East (2021-2030)
• Table 32: Proteomics Market Analysis in Africa (2021-2030)
• Table 33: Proteomics Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Proteomics Market
• Figure 3: Proteomics Market Analysis in Global (2021-2030)
• Figure 4: Proteomics Market Analysis in Global by Product Type (2021-2030)
• Figure 5: Proteomics Market Analysis in Global by Application (2021-2030)
• Figure 6: Proteomics Market Analysis in Global by End-User (2021-2030)
• Figure 7: Proteomics Market Analysis in Global by Geography (2021-2030)
• Figure 8: Proteomics Market Analysis in North America (2021-2030)
• Figure 9: Proteomics Market Analysis in North America by Country (2021-2030)
• Figure 10: Proteomics Market Analysis in the US (2021-2030)
• Figure 11: Proteomics Market Analysis in Canada (2021-2030)
• Figure 12: Proteomics Market Analysis in Mexico (2021-2030)
• Figure 13: Proteomics Market Analysis in Europe (2021-2030)
• Figure 14: Proteomics Market Analysis in Europe by Country (2021-2030)
• Figure 15: Proteomics Market Analysis in France (2021-2030)
• Figure 16: Proteomics Market Analysis in Germany (2021-2030)
• Figure 17: Proteomics Market Analysis in the UK (2021-2030)
• Figure 18: Proteomics Market Analysis in Italy (2021-2030)
• Figure 19: Proteomics Market Analysis in Spain (2021-2030)
• Figure 20: Proteomics Market Analysis in the Rest of Europe (2021-2030)
• Figure 21: Proteomics Market Analysis in Asia-Pacific (2021-2030)
• Figure 22: Proteomics Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 23: Proteomics Market Analysis in China (2021-2030)
• Figure 24: Proteomics Market Analysis in Japan (2021-2030)
• Figure 25: Proteomics Market Analysis in India (2021-2030)
• Figure 26: Proteomics Market Analysis in Australia (2021-2030)
• Figure 27: Proteomics Market Analysis in South Korea (2021-2030)
• Figure 28: Proteomics Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 29: Proteomics Market Analysis in the Rest of the World (2021-2030)
• Figure 30: Proteomics Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 31: Proteomics Market Analysis in the Middle East (2021-2030)
• Figure 32: Proteomics Market Analysis in Africa (2021-2030)
• Figure 33: Proteomics Market Analysis in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Market Opportunities
• Figure 37: PORTER's Five Force Analysis

Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various chronic diseases and the rising demand for personalized medicine across the globe

The global proteomics market is estimated to grow at a CAGR of 13.54% during the forecast period from 2024 to 2030. The proteomics market is observing significant market growth primarily due to the growing demand for personalized medicines to treat various chronic or targeted diseases. Further, the increasing need for advanced diagnostics in targeted disease treatment, the high prevalence of various target diseases such as cancer, cardiovascular diseases (CVDs), respiratory diseases, and chronic kidney diseases (CKD) across the world, and the increasing focus on product usage in drug designing, biomarker discoveries, and clinical diagnostics for the diagnosis and treatment of diseases will create the need for proteomics in the market. Additionally, the increasing product and service launches and approvals, the presence of key players in the market, and other factors will create a requisite for proteomics in the market. Lastly, the increasing overall healthcare sector, drug discovery, and surging investments by key players in the healthcare industry will in turn increase the research & developmental activities, ultimately affecting the demand certainly. Therefore, the market of proteomics is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Proteomics Market Dynamics:

One of the key aspects driving the proteomics market is the rising prevalence of various chronic diseases such as cancer, cardiovascular diseases, and others.

For instance, according to the World Health Organization (WHO) 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The new cases of breast cancer in 2020 were 2.26 million cases, across the globe. The same source stated that lung cancer accounted for 2.21 million new cases, colon and rectum cancer for 1.93 million new cases, prostate cancer with 1.41 million new cases, skin cancer accounted for 1.20 million new cases, and stomach cancer new cases were 1.09 million in 2020, globally. Further, according to WHO 2022, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year.

Thus, owing to the increasing prevalence of various life-threatening diseases and increasing demand for personalized therapies resulting in a positive impact on the market of proteomics as proteomics holds great promise in contributing to the prevention and cure of cancer because it provides unique tools for the discovery of biomarkers and therapeutic targets. Therefore, the increasing prevalence of chronic diseases will increase the demand for personalized medicine, eventually leading to an increased demand for proteomics in the market.

The increasing investments in proteomics R&D are one of the prominent growth drivers of the proteomics market. In 2022, the National Institutes of Health (NIH) of the United States provided USD 45 billion for medical research. This funding was intended to support life sciences research that sought to understand the fundamental processes by which diseases develop, such as the identification of biomarkers that indicate the presence of disease or the identification of the gene/protein responsible for the disease. Also, in 2020, Novo Nordisk Foundation was awarded the University of Copenhagen grant of up to USD 1.5 million to establish a mass spectrometry facility, which is a significant step forward in protein research. Thus, such investments and funding by the government and key players across the globe will increase the research & developmental activities, which in turn will affect the market of proteomics.

Further, rising healthcare costs, growing demand for tailored medication, and rising rates of genetic illnesses will increase the demand for proteomics during the forecast period.

Therefore, the factors stated above collectively will drive the overall proteomics market during the forecast period from 2024-2030.

However, the high cost of instruments, the presence of ambiguous regulatory framework, and others may prove to be challenging factors for the proteomics market growth.

The proteomics market was positively impacted during the period of the COVID-19 pandemic. During the initial stage of the pandemic, the demand for proteomics instruments and services suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. However, the proteomics techniques and instruments were used in the development of the Covid-19 vaccine to research the biomarker for vaccine development. Moreover, the proteomic approach was well suited for studying COVID-19 since it can provide quantitation and differential expression of proteins and their post-translational modifications. Thus, as the research for the COVID-19 vaccine increases, the demand for proteomics instruments and services upsurges considerably. Likewise, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and with the increasing demand of proteomics for research & development activities, the demand for proteomics increases and is anticipated to do the same during the forecast period from 2022 - 2028.

Proteomics Market Segment Analysis:

Proteomics Market by Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, and Other], Reagents & Consumables, and Software & Services), Application (Clinical Diagnostics, Drug Discovery, and Others), End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product type segment of the proteomics market, the electrophoresis segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the rising availability of technologically advanced instrumentation in the market, rising instrument launches and approvals in the market, and rising demand for electrophoresis in research & developmental activities.

Electrophoresis is one of the most conventional techniques used in biotechnology, which separates the particles based on the charge and size they possess. This technology can be used for the diagnosis of various diseases, DNA sequencing, analysis of antibodies and steroids, and other medical research activities. Moreover, the electrophoresis technique is used to identify many proteins that are significant for improved characterization of tumor progression and molecular specificity of both lung cancer subtypes. As a result of electrophoresis, it is possible to distinguish proteins from tumor cells, which aids in tumor diagnosis and may contribute to the segment's growth.

Further, various other strategic steps taken by the key players in the market will help in increasing the demand for electrophoresis. For instance, in September 2020, miniPCR bio launched GELATO, a gel electrophoresis system, a type of electrophoresis with an integrated blue light with transillumination technology, allowing simultaneous nucleic acid separation.

Therefore, owing to the above-mentioned factors, the demand for electrophoresis rises, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global proteomics market during the forecast period.

North America is expected to dominate the overall Proteomics Market:

Among all the regions, North America is expected to dominate global proteomics in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing need for advanced diagnostics in targeted disease treatment, the rising prevalence of target diseases across the world, and the presence of key market players in the region are the key reasons which act as a supportive factor for the North America proteomics market growth.

For instance, according to the Cancer Facts & Figures 2022, in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. The increasing incidence of cancer in the region will increase the demand for proteomics as the instrumentation is employed in the detection of tumors in a patient.

Additionally, the increasing number of novel and next-generation therapeutics approved in the region will increase the demand for proteomics. Also, the rising investments in the field of personalized medicine, the presence of globally leading market players, increasing research in the fields of omics, and the rising investments in the area of structure-based drug design will in turn increase the demand for proteomics in the North America.

Further, increasing product launches of various technologically advanced proteomics instrumentations and strategic steps such as collaboration, acquisition, and partnership by key players in the region will ultimately increase its demand. For instance, in March 2022, Thermo Fisher Scientific, the world leader in serving science, and Protein Metrics, a developer of world-class software tools for protein characterization, entered into a non-exclusive co-marketing agreement to provide advanced mass spectrometry data processing and analysis capabilities to drive innovation across the full spectrum of biopharmaceutical and proteomics applications, from research and development to quality control.

Therefore, the interplay of the aforementioned factors would provide a conducive growth environment for the North American region in the proteomics market.

Proteomics Market Key Players:

Some of the key market players operating in the proteomics market include Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Danaher., General Electric Company, Bruker, Merck KGaA, Promega Corporation., Waters Corporation., Illumina, Inc., Creative Proteomics., VProteomics, HORIBA, Ltd., Applied Biomics., Fios Genomics., and others.

Recent Developmental Activities in the Proteomics Market:

In January 2022, PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis by mass spectrometry, raised Euro 13.5m in a Series B financing round provided by Bruker Corporation.

In August 2022, Bruker Corporation, announced the launch of the new nanoEluteR 2 nano-LC, of MetaboScapeR and TASQR 2023 software supporting fluxomics, and of the latest advances in PaSER(TM)'s intelligent acquisition to enhance research in protein-protein interactions (PPIs) and metaproteomics applications.

In February 2020, Applied Biomics, Inc., a leading Proteomics service provider, added an HCP profiling analysis using their well-established high-resolution, large format 2-Dimensional Differential In-Gel Electrophoresis (2D DIGE) platform.

Key Takeaways from the Proteomics Market Report Study

Market size analysis for current proteomics market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Proteomics market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global proteomics market.

Various opportunities available for the other competitor in the proteomics market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current proteomics market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for proteomics market growth in the coming future?

Target Audience who can be benefited from this Proteomics Market Report Study

Proteomics products providers

Research organizations and consulting companies

Proteomics-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in proteomics

Various end users who want to know more about the proteomics market and the latest technological developments in the proteomics market.

Frequently Asked Questions for the Proteomics Market:

1. What is proteomics?

The study of protein structure and function is known as proteomics. Proteomics is concerned with topics such as which proteins are expressed, when and where they are expressed, what their structures are in both active and inactive states, what roles they play in cell life, and how they interact with other proteins and molecules.

2. What is the global market for proteomics?

The global proteomics market is estimated to grow at a CAGR of 13.54% during the forecast period from 2024 to 2030.

3. What are the drivers for the global proteomics market?

The proteomics market is witnessing positive market growth owing to the factors such as growing demand for personalized medicines, increasing need for advanced diagnostics in targeted disease treatment, high prevalence of target diseases across the world, increasing focus on product usage in drug designing, biomarker discoveries, and clinical diagnostics for the diagnosis and treatment of diseases, increasing product launches and approvals, presence of key players in the market, and others will create an exigency for the proteomics market.

4. Who are the key players operating in the global proteomics market?

Some of the key market players operating in the proteomics market include Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Danaher., General Electric Company, Bruker, Merck KGaA, Promega Corporation., Waters Corporation., Illumina, Inc., Creative Proteomics., VProteomics, HORIBA, Ltd., Applied Biomics., Fios Genomics., and others.

5. Which region has the highest share of the proteomics market?

Among all the regions, North America is estimated to amass a significant revenue share in the global Proteomics market. This can be ascribed to the increasing need for advanced diagnostics in targeted disease treatment, the rising prevalence of target diseases across the world, and the presence of key market players in the region are the reasons which act as a supportive factors for the North America proteomics market growth.

Table of Contents

1.Proteomics Market Report Introduction

2. Proteomics Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Proteomics Market Key Factors Analysis

• 4.1. Proteomics Market Drivers
  • 4.1.1. Growing demand for personalized medicines
  • 4.1.2. Increasing need for advanced diagnostics in targeted disease treatment
  • 4.1.3. High prevalence of target diseases across the world
  • 4.1.4. Increasing focus on product usage in drug designing, biomarker discoveries, and clinical diagnostics for the diagnosis and treatment of diseases
• 4.2. Proteomics Market Restraints and Challenges
  • 4.2.1. High cost of instruments
  • 4.2.2. Presence of an ambiguous regulatory framework
• 4.3. Proteomics Market Opportunities
  • 4.3.1. Increased R&D expenditure and government funding for proteomics in emerging countries
  • 4.3.2. Increasing demand for nanoproteomics field

5. Proteomics Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Proteomics Market

7. Proteomics Market Layout

• 7.1. By Product & Services
  • 7.1.1. Instrumentation Technology
    • 7.1.1.1. Spectroscopy
    • 7.1.1.2. Chromatography
    • 7.1.1.3. Electrophoresis
    • 7.1.1.4. Protein Microarrays
    • 7.1.1.5. X-Ray Crystallography
    • 7.1.1.6. Other
  • 7.1.2. Reagents & Consumables
  • 7.1.3. Software and Services
• 7.2. By Application
  • 7.2.1. Clinical Diagnostics
  • 7.2.2. Drug Discovery
  • 7.2.3. Others
• 7.3. By End-User
  • 7.3.1. Hospitals
  • 7.3.2. Clinical Laboratories
  • 7.3.3. Pharmaceutical Companies
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Proteomics Market in USD million (2021-2030)
    • 7.4.1.2. Canada Proteomics Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Proteomics Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Proteomics Market in USD million (2021-2030)
    • 7.4.2.2. Germany Proteomics Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Proteomics Market in USD million (2021-2030)
    • 7.4.2.4. Italy Proteomics Market in USD million (2021-2030)
    • 7.4.2.5. Spain Proteomics Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Proteomics Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Proteomics Market in USD million (2021-2030)
    • 7.4.3.2. Japan Proteomics Market in USD million (2021-2030)
    • 7.4.3.3. India Proteomics Market in USD million (2021-2030)
    • 7.4.3.4. Australia Proteomics Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Proteomics Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Proteomics Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Proteomics Market in USD million (2021-2030)
    • 7.4.4.2. Africa Proteomics Market in USD million (2021-2030)
    • 7.4.4.3. South America Proteomics Market in USD million (2021-2030)

8. Proteomics Market Company and Product Profiles

• 8.1. Agilent Technologies, Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Thermo Fisher Scientific, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bio-Rad Laboratories, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Danaher.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. General Electric Company
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Bruker
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Merck KGaA
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Promega Corporation.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Waters Corporation.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5. Entropy
• 8.10. Illumina, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Creative Proteomics.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. VProteomics
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. HORIBA, Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Applied Biomics.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Fios Genomics.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us